Innovative biomedical scientist specializing in CRISPR/Cas based genetic engineering with a focus on single nucleotide precision variant detection. Pioneered the development of the FnCas9 Editor Linked Uniform Detection Assay (FELUDA), a groundbreaking low-cost SARS-CoV-2 detection test, and the Rapid Variant Assay (RAY) for robust diagnosis of monogenic and infectious disorders. Currently exploring novel applications of CRISPR/Cas9 technology, including the concept of the CRISPR/Cas9 Utilizing Human Body Sticker (CRISticker) for visually identifying pathogenic variants in a sequencing-free manner. Excited about leveraging multiplexable assays to advance clinical research, disease genotyping, microbial infection surveillance, food safety, and industrial biotechnology.
eChai Ventures partners with select brands as their growth partner - working together to explore new ideas, open doors, and build momentum across the startup ecosystem.
Oizom offers Environmental IoT and Environmental Ai solutions for a sustainable future.